Gabriela Chiorean

Appointments and Affiliations

 
 
University of Washington/Seattle Cancer Care Alliance
Clinical Research GI Oncology Program
Director
 
Fred Hutchinson Cancer Research Center
Clinical Research Division
Associate Member
 
University of Washington
Full Professor of Medicine
Professional Headshot of Gabriela Chiorean

Mailing Address

Seattle Cancer Care Alliance
Medical Director's Office
825 Eastlake Ave E
Mail Stop G4-830
Seattle, WA 98109-1023

Contact

Phone: (206) 288-6248

gchiorea@seattlecca.org

Degrees

1987-1993: MD (Summa Cum Laude), University of Medicine and Pharmacy Cluj-Napoca, Romania
1983-1987: Baccalaureate, "Gheorghe Lazar College" Mathematics and Physics High School, Sibiu, Romania

Memberships

American Association for Cancer Research
American Society of Clinical Oncology

Honors and Awards

2016: Pancreatic Cancer Action Network-Puget Sound Chapter, Purple Stride Honorary Chair
2015: 3rd International Pancreas Cancer Forum/Workshop, Milano, Italy
2015: Pancreatic Cancer Action Network-Puget Sound Chapter, Purple Stride Honorary Chair
2014: Danny Danielson Translation Innovation Award - Hoosier Cancer Research Network
2008: Outstanding Young Clinician Award - Indiana University, Department of Medicine
2006: ASCO/AACR/NCI/FDA Workshop Award for Accelerating Anticancer Agent Development and Validation Workshop, Bethesda, MD
2006: Danielson Award for Clinical Research - Walther Cancer Institute, Indianapolis, IN
2001: Fellow Award - Mayo Clinic Hematology-Oncology Reviews, Amelia Island, FL
2001: Fellow Travel Award - American Society of Hematology

Board Certifications

2002-2022: ABIM Subspecialty Board of Medical Oncology
2002-2012: ABIM Subspecialty Board of Hematology
1998-2008: American Board of Internal Medicine (ABIM)

Licensure

2012-present: Washington State Medical License
2004-2013: Indiana State Medical License
1999-2004: Minnesota State Medical License
1995-1997: Michigan State Medical License

Previous Positions

2010-2012: Co-Director, Multi-disciplinary Pancreatic Cancer Clinic, Indiana University Simon Cancer Center, Indianapolis, IN
2008-2012: Medical Director, GI Oncology Program, Indiana University Simon Cancer Center, Indianapolis, IN
2008-2012: Medical Director, Phase I Program, Indiana University Simon Cancer Center, Indianapolis, IN
2006-2012: Assistant Professor of Medicine, Department of Medicine, Division of Hematology-Oncology, Indiana University, Indianapolis, IN
2004-2006: Assistant Professor of Clinical Medicine, Department of Medicine, Division Hematology-Oncology, Indiana University, Indianapolis, IN
2002-2004: Assistant Professor of Medicine, Department of Medicine, Division of Hematology-Oncology-Transplantation, University of Minnesota, Minneapolis, MN

Funding

  • New Link Genetics: A phase 2 study of neoadjuvant chemotherapy followed by stereotactic body radiation therapy (SBRT) with Aigenpantucel-L (HyperAcute-Pancreas) immunotherapy in subjects with borderline resectable pancreatic cancer, 2015
  • Ignyta: A phase 1/2A, multicenter, open-label study of oral entrectenib (RXDX-1 01) in adult patients with locally advanced or metastatic cancer confimed to be positive for NTRK1, NTRK2, NTRK3, ROS 1, or ALK molecular alterations, 2015
  • Celgene: A phase 1, open-label, multicenter, safety study of nivolumab (BMS-936558) in combination with nab-paclitaxel plus or minus gemcitabine in pancreatic cancer, nab-paclitaxel/carboplatin in stage Illb/lV non-small cell lung cancer or nab-paclitaxel in recurrent metastatic breast cancer, 2015
  • BMS/F-Star Pharmaceuticals: Phase I multiple ascending dose study of anti-HER2 Fcab FS 1 02 in breast, gastric, and other solid tumors, 2015
  • Boehringer-Ingelheim: Phase Illb study of afatinib (BIBW 2992), an irreversible EGFR/HER2 inhibitor in combination with capecitabine for advanced solid tumors and pancreatico-biliary tract cancers, 2015 to 2018
  • Solid Tumors Translational Research Grant (STIR): NWBiotrusUCenter for Accelerated Translation in Pancreas Cancer (CATPAC) biorepository, 2015 to 2016
  • Celgene: A phase 3 multicenter, open-label, randomized study of nabpaclitaxel plus gemcitabine versus gemcitabine alone as adjuvant therapy in subjects with surgically resected pancreatic adenocarcinoma, 2014 to 2016
  • Solid Tumor Translational Research Grant (STIR): Pancreatic Cancer Molecular Tumor Profiling Grant, 2014 to 2016
  • NCI/CTSU: PROSPECT N1048: A phase 11/111 trial of neoadjuvant FOLFOX with selective use of combined modality chemoradiation versus preoperative combined modality chemoradiation for locally advanced rectal cancer patients undergoing low anterior resection with total meso rectal excision, 2013 to 2018
  • NCCN: A phase IIII study of the combination of temozolomide and pazopanib in advanced pancreatic neuroendocrine tumors (PNET), 2013 to 2017
  • NCI/SWOG: SWOG1313, A phase Ib/ll randomized study of modified FOLFIRINOX + pegylated recombinant human hyaluronidase (PEGPH20) versus modified FOLFIRINOX alone in patients with good performance status metastatic pancreatic adenocarcinoma, 2014
  • NCl/Cancer Center Consortium Grant (CCSG): DNA Repair Pathway Assessment by BROCNHomologous Recombination Deficiency (BROCA-HR) Assay in Pancreatic Adenocarcinoma, 2013 to 2016
  • Walther Cancer Institute; Indiana University; Novartis, Amgen: Phase I study of dual Insulin-like Growth Factor Receptor and mTOR Inhibition with AMG 479 plus RAD001 in patients with refractory solid tumors, 2009 to 2016

Recent Publications

2017
2016
Coveler AL, Herman JM, Simeone DM, Chiorean GE.  2016.  Localized Pancreatic Cancer: Multidisciplinary Management.. American Society of Clinical Oncology educational book / ASCO. American Society of Clinical Oncology. Meeting. 35:e217-26. Abstract
2015
2014
Tempero MA, Malafa MP, Behrman SW, Benson AB, Casper ES, Chiorean GE, Chung V, Cohen SJ, Czito B, Engebretson A et al..  2014.  Pancreatic adenocarcinoma, version 2.2014.. Journal of the National Comprehensive Cancer Network : JNCCN. 12(8):1083-93. Abstract

Coming Soon: New Profiles System!

In preparation for the launch of our new profiles system, we are freezing updates to these profiles. If you have any questions, please email library@fredhutch.org.

Researcher Profiles

 

Related Websites

 

Scientific Divisions